Skip to main content

Table 1 Secondary outcomes

From: No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis

 

Success group

Failure group

Primoinfections [n]

33

16

Age at diagnosis [years]

9.3

9.1

 

p value 0.842 (T test)

Symptoms at diagnosis [%]

81.8

87.5

 

p value 0.118 (McNemar)

 Cough [%]

66.7

87.5

 Upper respiratory tract infect. [%]

39.4

25.0

 Dyspnea [%]

3.0

12.5

 Fever [%]

3.0

12.5

Diagnostic methods [%]

 Sputum samples

69.7

75.0

 Oropharyngeal swab

30.3

25.0

 

p value 0.831 (McNemar)

 

Diagn.

Follow-up

Diagn.

Follow-up

FEV1 [%]

 Mean

107.7

107.8

104.7

99.1

 Median

103

103

104

99.5

 p value

0.772 (Wilcoxon)

0.312 (T test)

BMI [kg/m2]

 Mean

16.3

16.6

16.9

17.1

 Median

15.8

16.0

16.6

16.2

 p value

0.024 (Wilcoxon)

0.083 (Wilcoxon)

  1. Among symptomatic patients, distribution of most frequent symptoms. A patient may have more than one symptom (in italics)